Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, Texas / Mar 12, 2024 / Business Wire / Biote (NASDAQ: BTMD), a leading... Read More